What Contributes to Appetite?

Take our Emotional Eating Test

Find a therapist near me

AI helped identify BRP, a naturally occurring peptide that may reduce appetite.

BRP reduced food intake and body fat in animals without clear nausea or muscle loss.

BRP appears to act through brain pathways different from those targeted by GLP-1 drugs.

Despite promising animal results, BRP has not yet been tested for safety or efficacy in humans.

The success of drugs such as Ozempic and Wegovy has transformed how scientists think about obesity. These medications demonstrate that appetite and body weight are not simply products of willpower. They are regulated by biological signals connecting the brain, digestive system, pancreas, and other organs.

But the same broad biological reach that makes these drugs effective can also produce unwanted effects, including nausea, constipation, slowed digestion, and loss of lean body mass.

Now, researchers at Stanford Medicine have identified a naturally occurring molecule that may suppress appetite through a different, and potentially more targeted, pathway. The molecule, called BRP (short for BRINP2-related peptide), reduced food intake and body weight in mice and pigs without producing several of the adverse effects associated with existing weight-loss medications.

Headlines have understandably referred to BRP as a “natural Ozempic.” That comparison captures the excitement surrounding the discovery, but it also risks getting ahead of the science. BRP has not yet been shown to be safe or effective in humans.

What may be most important about the research is not that scientists have found an immediate replacement for semaglutide. It is that artificial intelligence (AI) helped uncover a previously hidden biological signal that may lead to an entirely new class of obesity treatments.

Searching the........

© Psychology Today